-
Mashup Score: 7Monoclonal Antibody Receives Emergency Use Authorization for Preventing COVID-19 in High-Risk Patients - 1 month(s) ago
Although severe COVID-19 has become less common than early in the pandemic, immunosuppressed patients remain at excess risk for poor outcomes. In late
Source: www.jwatch.orgCategories: General Medicine News, General Journals & SocietTweet
Pemivibart, a long-acting antispike monoclonal antibody, has received emergency use authorization for preventing #COVID19 in high-risk patients. https://t.co/XPR9adnf3s #IDTwitter @dan_dkauld https://t.co/OfLWJRstoZ